Business Context and Reporting Period
This Form 8-K was filed by Bristol-Myers Squibb Company on September 21, 2006. The report addresses a specific legal development regarding the company's product PLAVIX (clopidogrel bisulfate) in collaboration with sanofi-aventis.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The primary material event is a legal ruling concerning the generic version of PLAVIX:
- The United States Court of Appeals for the Federal Circuit denied a motion by Apotex to stay a preliminary injunction.
- The injunction, issued on August 31, 2006, by the U.S. District Court for the Southern District of New York, orders Apotex to halt sales of its generic clopidogrel bisulfate product.
Outlook, Risks, and Management Commentary
The Court of Appeals has established an expedited schedule for Apotex's appeal of the preliminary injunction. Oral arguments are scheduled for October 31, 2006. The filing highlights the ongoing legal risk associated with generic competition for PLAVIX but confirms the current enforcement of the sales halt against Apotex.
Investor Verification Checklist
- Verify the status of the preliminary injunction against Apotex regarding PLAVIX.
- Monitor the outcome of the oral arguments scheduled for October 31, 2006.
- Review the attached press release (Exhibit 99.1) for detailed statements from Bristol-Myers Squibb and sanofi-aventis.